Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Caveolin-1 gene therapy - University of California San Diego

X
Drug Profile

Caveolin-1 gene therapy - University of California San Diego

Alternative Names: ET 101 - Eikonoklastes Therapeutics; SynCav1 - Eikonoklastes Therapeutics

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Eikonoklastes Therapeutics; University of California, San Diego
  • Class Antidementias; Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Caveolin 1 expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Traumatic brain injuries
  • Research Huntington's disease; Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 16 Jan 2024 Preclinical development is ongoing in Amyotrophic-lateral-sclerosis in USA (Parenteral) (Eikonoklastes Therapeutics pipeline; January 2024)
  • 16 Jan 2024 Eikonoklastes Therapeutics plans a First-in-human clinical trial in 2024 (Eikonoklastes Therapeutics pipeline; January 2024)
  • 28 Aug 2023 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top